Please wait while we open this resource.
K
Clinical reviews
CURRENT AND EMERGING PHARMACOTHERAPY FOR THE MANAGEMENT OF HYPERTROPHIC CARDIOMYOPATHY
New York Medical College, Rowan-Virtua School of Osteopathic Medicine, MedStar Union Memorial Hospital, Tufts University School of Medicine, Westchester Medical Center, Atlantic Health
PDF202313 pages750 KB
Hypertrophic cardiomyopathy (HCM) is one of the most prevalent genetic causes of heart disease, characterized by abnormal thickening of the heart muscle. Despite its significance, management options have seen limited advancements since its initial description. This review discusses various pharmacological treatments, including recent clinical trials and emerging therapies aimed at improving patient outcomes in HCM.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology